s/hubermanlabOBESITY DRUGS•1d
103
votes
4.1k
seen
Lilly’s eloralintide-Zepbound combo drove more weight loss, but side effects ended treatment for up to 27%
The added weight loss came with a tolerability problem: Lilly’s eloralintide-Zepbound combination produced 23.3% average weight loss at 48 weeks, versus 14.8% for Zepbound alone in adults with obesity and Type 2 diabetes. The combo also improved blood sugar, but side effects led 11% to 27% of participants to stop treatment.
That leaves Lilly trying to carry the stronger result into a larger trial without losing patients along the way. Lilly said it plans to start Phase 3 studies of the co-formulated therapy by the end of 2026.
That leaves Lilly trying to carry the stronger result into a larger trial without losing patients along the way. Lilly said it plans to start Phase 3 studies of the co-formulated therapy by the end of 2026.
Timeline2
1d
Lilly reported 23.3% average weight loss with the eloralintide-Zepbound combination versus 14.8% with tirzepatide alone at 48 weeks.
1d
Lilly said it plans to initiate Phase 3 studies of the eloralintide-Zepbound co-formulation by the end of 2026.
1 comment
1d